FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Slides:

Advertisements

Similar presentations

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

Advertisements

New ESC/EACTS guidelines on myocardial revascularisation Indications for coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Coronary revascularisation rate (total 5

Figure 4 Observational studies on multiple treatment strategies

The recommended approach to patients with chronic obstructive pulmonary disease (COPD) presenting with dyspnoea. The recommended approach to patients with.

Tornado diagram of one-way deterministic sensitivity analysis.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Nat. Rev. Cardiol. doi: /nrcardio

Flow Diagram of the Trial Selection Process

Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. There.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Glenn N. Levine et al. JACC 2011;58:e44-e122

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Representative images of coronary angiography and fractional flow reserve (FFR) from a patient who showed no resting ECG abnormality. Representative images.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Leslee J. Shaw et al. JIMG 2010;3:

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

The fractional flow reserve (FFR) values according to increasing risks of the Multifunction CardioGram (MCG) scores. The fractional flow reserve (FFR)

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Javier Escaned et al. JCIN 2018;11:

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Forest plot illustrating the risk ratio of myocardial infarction

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Performance of the Manchester Acute Coronary Syndromes decision rule in the derivation study. Performance of the Manchester Acute Coronary Syndromes decision.

Cardioprotective effects of ivabradine administration in the setting of acute coronary syndromes and myocardial infarction. Cardioprotective effects of.

Presentation transcript:

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). (A) mace; (B) recurrent MI; (C) unplanned revascularisation; (D) cardiovascular mortality; (E) non-culprit vessel only versus both culprit and non-culprit vessel. ACS, acute coronary syndrome; FFR, fractional flow reserve; MI, myocardial infarction; PCI, percutaneous coronary intervention. Kevin P Liou et al. Open Heart 2019;6:e000934 ©2019 by British Cardiovascular Society